PE20091655A1 - Farmaco para el cancer de higado - Google Patents
Farmaco para el cancer de higadoInfo
- Publication number
- PE20091655A1 PE20091655A1 PE2009000413A PE2009000413A PE20091655A1 PE 20091655 A1 PE20091655 A1 PE 20091655A1 PE 2009000413 A PE2009000413 A PE 2009000413A PE 2009000413 A PE2009000413 A PE 2009000413A PE 20091655 A1 PE20091655 A1 PE 20091655A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- sequence
- liver cancer
- amino acid
- acid sequence
- Prior art date
Links
- 201000007270 liver cancer Diseases 0.000 title abstract 3
- 208000014018 liver neoplasm Diseases 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 150000001413 amino acids Chemical group 0.000 abstract 6
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 abstract 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 abstract 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 abstract 1
- 239000012829 chemotherapy agent Substances 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 229960003787 sorafenib Drugs 0.000 abstract 1
- 229960001796 sunitinib Drugs 0.000 abstract 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 abstract 1
- 230000004580 weight loss Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONTIENE: A) UN AGENTE QUIMIOTERAPEUTICO INHIBIDOR DE MULTIPLES CINASAS TAL COMO SORAFENIB O SUNITINIB; Y B) UN ANTICUERPO HUMANIZADO ANTI-GLIPICANO 3 QUE COMPRENDE: a) LA REGION VARIABLE DE CADENA PESADA QUE COMPRENDE i) CDR1 QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DE LA ID SEC Nº: 5, ii) CDR2 QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DE LA ID SEC Nº: 6, iii) CDR3 QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DE LA ID SEC Nº: 7; Y b) LA REGION VARIABLE DE CADENA LIGERA QUE COMPRENDE i) CDR1 QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DE LA ID SEC Nº: 8, ii) CDR2 QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DE LA ID SEC Nº: 24, iii) CDR3 QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DE LA ID SEC Nº: 25, DONDE EL ANTICUERPO ALIVIA UN EFECTO SECUNDARIO CAUSADO POR UN TRATAMIENTO DE CANCER DE HIGADO TAL COMO LA PERDIDA DE PESO. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DEL CANCER DE HIGADO
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008098309 | 2008-04-04 | ||
| PCT/JP2008/002690 WO2009041062A1 (ja) | 2007-09-28 | 2008-09-26 | 血漿中動態が改善されたグリピカン３抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20091655A1 true PE20091655A1 (es) | 2009-11-04 |
Family
ID=41135076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2009000413A PE20091655A1 (es) | 2008-04-04 | 2009-03-19 | Farmaco para el cancer de higado |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20110104157A1 (es) |
| EP (1) | EP2275135A4 (es) |
| JP (2) | JP5306327B2 (es) |
| KR (1) | KR101612139B1 (es) |
| CN (1) | CN102046200B (es) |
| AR (1) | AR071003A1 (es) |
| AU (1) | AU2009233301B2 (es) |
| BR (1) | BRPI0911147A2 (es) |
| CA (1) | CA2720359A1 (es) |
| CL (1) | CL2009000647A1 (es) |
| CO (1) | CO6300964A2 (es) |
| CR (1) | CR11769A (es) |
| EC (1) | ECSP10010589A (es) |
| IL (1) | IL208451A0 (es) |
| MA (1) | MA32360B1 (es) |
| MX (1) | MX2010010954A (es) |
| NZ (1) | NZ588913A (es) |
| PE (1) | PE20091655A1 (es) |
| RU (1) | RU2523897C2 (es) |
| SG (1) | SG189754A1 (es) |
| TW (1) | TWI468175B (es) |
| UA (1) | UA103614C2 (es) |
| WO (1) | WO2009122667A1 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2353967T3 (es) * | 2004-07-09 | 2011-03-08 | Chugai Seiyaku Kabushiki Kaisha | Anticuerpo anti-glipicano 3 . |
| WO2006046751A1 (ja) * | 2004-10-26 | 2006-05-04 | Chugai Seiyaku Kabushiki Kaisha | 糖鎖改変抗グリピカン３抗体 |
| US20070087005A1 (en) | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
| WO2009041062A1 (ja) * | 2007-09-28 | 2009-04-02 | Chugai Seiyaku Kabushiki Kaisha | 血漿中動態が改善されたグリピカン３抗体 |
| WO2013181543A1 (en) * | 2012-06-01 | 2013-12-05 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | High-affinity monoclonal antibodies to glypican-3 and use thereof |
| EP4119947A1 (en) | 2012-12-21 | 2023-01-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy |
| TWI693073B (zh) | 2012-12-21 | 2020-05-11 | 日商中外製藥股份有限公司 | 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑 |
| CN106459959A (zh) | 2014-05-08 | 2017-02-22 | 中外制药株式会社 | 对gpc3靶向治疗剂疗法有效的患者施用的gpc3靶向治疗剂 |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| RU2683020C2 (ru) * | 2014-11-11 | 2019-03-26 | Петр Иванович Никитин | Субстанция и способ для модуляции активности агента в организме |
| CN113274386A (zh) | 2015-06-30 | 2021-08-20 | 艾格集团国际公司 | 氯喹和克立咪唑化合物用于治疗炎症和癌症的用途 |
| JP7096667B2 (ja) | 2015-07-01 | 2022-07-06 | 中外製薬株式会社 | Ｇｐｃ３標的治療剤が有効である患者に投与されるｇｐｃ３標的治療剤 |
| AU2016304060B2 (en) * | 2015-08-03 | 2022-09-29 | Crage Medical Co., Limited | Antibody against glypican-3 and application thereof |
| US11767362B1 (en) * | 2016-03-15 | 2023-09-26 | Chugai Seiyaku Kabushiki Kaisha | Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies |
| JP7382922B2 (ja) | 2017-09-20 | 2023-11-17 | 中外製薬株式会社 | Ｐｄ－１系結合アンタゴニストおよびｇｐｃ３標的化剤を使用する併用療法のための投与レジメン |
| EP3825404A4 (en) * | 2018-07-17 | 2022-04-13 | Noile-Immune Biotech, Inc. | Anti-gpc3 single-chain antibody-containing car |
| KR102154683B1 (ko) * | 2019-11-08 | 2020-09-11 | 주식회사 압타머사이언스 | 글리피칸-3 특이적 변형 압타머 및 이의 용도 |
| EP4121517A4 (en) * | 2020-03-18 | 2024-08-07 | Eutilex Co., Ltd. | IL-18-SECRETING GPC3 CAR-T CELLS AND METHODS OF MAKING AND USING THE SAME |
| KR20220155588A (ko) * | 2020-03-18 | 2022-11-23 | 주식회사 유틸렉스 | Gpc3 car-t 세포 조성물 및 이의 제조 및 사용 방법 |
| US20240301085A1 (en) * | 2021-02-10 | 2024-09-12 | Simcere Zaiming Pharmaceutical Co., Ltd. | Humanized gpc3 antibody and application thereof |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| JPS6459878A (en) | 1987-08-31 | 1989-03-07 | Matsushita Electric Industrial Co Ltd | Semiconductor laser protective circuit |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
| CA2089661C (en) | 1990-08-29 | 2007-04-03 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE69229477T2 (de) | 1991-09-23 | 1999-12-09 | Cambridge Antibody Technology Ltd., Melbourn | Methoden zur Herstellung humanisierter Antikörper |
| ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| CA2131151A1 (en) | 1992-03-24 | 1994-09-30 | Kevin S. Johnson | Methods for producing members of specific binding pairs |
| SG48760A1 (en) | 1992-07-24 | 2003-03-18 | Abgenix Inc | Generation of xenogenetic antibodies |
| US5648267A (en) | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
| CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| AU690171B2 (en) | 1993-12-03 | 1998-04-23 | Medical Research Council | Recombinant binding proteins and peptides |
| EP0770628B9 (en) | 1994-07-13 | 2007-02-28 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin-8 |
| GB9425138D0 (en) * | 1994-12-12 | 1995-02-08 | Dynal As | Isolation of nucleic acid |
| KR100654645B1 (ko) | 1995-04-27 | 2007-04-04 | 아브게닉스, 인크. | 면역화된 제노마우스 유래의 인간 항체 |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| EP2278003B2 (en) | 1999-04-09 | 2020-08-05 | Kyowa Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| GB0017635D0 (en) * | 2000-07-18 | 2000-09-06 | Pharmacia & Upjohn Spa | Antitumor combined therapy |
| ES2620359T3 (es) | 2000-10-06 | 2017-06-28 | Kyowa Hakko Kirin Co., Ltd. | Células que producen unas composiciones de anticuerpo |
| US20030003097A1 (en) | 2001-04-02 | 2003-01-02 | Idec Pharmaceutical Corporation | Recombinant antibodies coexpressed with GnTIII |
| ES2399028T3 (es) * | 2001-06-22 | 2013-03-25 | Chugai Seiyaku Kabushiki Kaisha | Inhibidores de la proliferación celular que contienen anticuerpo anti-glipicano 3 |
| US7850990B2 (en) * | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| DE60216305T2 (de) * | 2001-10-03 | 2007-07-05 | Celator Pharmaceuticals, Inc. | Zusammensetzungen und Verfahren zur Abgabe von Arzneimittelkombinationen |
| US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20060088899A1 (en) * | 2002-05-31 | 2006-04-27 | Alvarez Vernon L | Combination chemotherapy with chlorotoxin |
| AU2002338020A1 (en) * | 2002-09-04 | 2004-03-29 | Chugai Seiyaku Kabushiki Kaisha | Antibody against blood-solubilized n-terminal peptide in gpc3 |
| JP2006523457A (ja) * | 2003-04-02 | 2006-10-19 | セレーター ファーマスーティカルズ、インク． | コンビネーション治療の個別化方法 |
| BRPI0511065A (pt) * | 2004-06-04 | 2007-12-26 | Pfizer Prod Inc | método para tratar crescimento de célula anormal |
| DE102004032634A1 (de) * | 2004-07-06 | 2006-02-16 | Sms Demag Ag | Verfahren und Einrichtung zum Messen und Regeln der Planheit und/oder der Bandspannungen eines Edelstahlbandes oder einer Edelstahlfolie beim Kaltwalzen in einem Vielwalzengerüst, insbesondere in einem 20-Walzen-Sendizimir-Walzwerk |
| JP4331227B2 (ja) * | 2004-07-09 | 2009-09-16 | 中外製薬株式会社 | 抗グリピカン３抗体 |
| ES2353967T3 (es) * | 2004-07-09 | 2011-03-08 | Chugai Seiyaku Kabushiki Kaisha | Anticuerpo anti-glipicano 3 . |
| US7871613B2 (en) * | 2004-08-24 | 2011-01-18 | Chugai Seiyaku Kabushiki Kaisha | Adjuvant therapy with the use of anti-glypican 3 antibody |
| WO2006046751A1 (ja) * | 2004-10-26 | 2006-05-04 | Chugai Seiyaku Kabushiki Kaisha | 糖鎖改変抗グリピカン３抗体 |
| EP2208783A1 (en) * | 2004-12-22 | 2010-07-21 | Chugai Seiyaku Kabushiki Kaisha | Method of producing an antibody using a cell in which the function of fucose transporter is inhibited |
| US8299252B2 (en) * | 2005-08-05 | 2012-10-30 | Chugai Seiyaku Kabushiki Kaisha | Pyrazolopyridine and pyrrolopyridine multikinase inhibitors |
| US20070087005A1 (en) * | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
| CA2627873A1 (en) * | 2005-10-31 | 2007-05-10 | Scott Wilhelm | Treatment of cancer with sorafenib |
| US20070185069A1 (en) * | 2005-11-14 | 2007-08-09 | Plum Stacy M | Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents |
| BRPI0707671A2 (pt) * | 2006-02-09 | 2011-05-10 | Daiichi Sankyo Co Ltd | composiÇço farmacÊutica anti-cÂncer |
| WO2007099988A1 (ja) * | 2006-02-28 | 2007-09-07 | Kyowa Hakko Kogyo Co., Ltd. | α-1,6-フコシルトランスフェラーゼ変異体とその用途 |
| EP4001409A1 (en) * | 2006-03-31 | 2022-05-25 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| CN105177091A (zh) * | 2006-03-31 | 2015-12-23 | 中外制药株式会社 | 用于纯化双特异性抗体的抗体修饰方法 |
| WO2007137170A2 (en) * | 2006-05-20 | 2007-11-29 | Seattle Genetics, Inc. | Anti-glypican-3 antibody drug conjugates |
| JP4640675B2 (ja) | 2006-06-20 | 2011-03-02 | 清水建設株式会社 | 空調システム |
| JP4463793B2 (ja) | 2006-10-10 | 2010-05-19 | 浜松ホトニクス株式会社 | 光検出装置 |
| KR101527342B1 (ko) * | 2007-07-17 | 2015-06-09 | 메다렉스, 엘.엘.시. | 글리피칸-3에 대한 단클론 항체 |
| US9096651B2 (en) * | 2007-09-26 | 2015-08-04 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
| WO2009041062A1 (ja) * | 2007-09-28 | 2009-04-02 | Chugai Seiyaku Kabushiki Kaisha | 血漿中動態が改善されたグリピカン３抗体 |
-
2009
- 2009-03-18 CL CL2009000647A patent/CL2009000647A1/es unknown
- 2009-03-19 JP JP2010505322A patent/JP5306327B2/ja not_active Expired - Fee Related
- 2009-03-19 CA CA2720359A patent/CA2720359A1/en not_active Abandoned
- 2009-03-19 BR BRPI0911147A patent/BRPI0911147A2/pt not_active IP Right Cessation
- 2009-03-19 UA UAA201013035A patent/UA103614C2/uk unknown
- 2009-03-19 AR ARP090100996A patent/AR071003A1/es unknown
- 2009-03-19 US US12/936,367 patent/US20110104157A1/en not_active Abandoned
- 2009-03-19 SG SG2013025549A patent/SG189754A1/en unknown
- 2009-03-19 TW TW98108942A patent/TWI468175B/zh not_active IP Right Cessation
- 2009-03-19 WO PCT/JP2009/001249 patent/WO2009122667A1/ja not_active Ceased
- 2009-03-19 CN CN200980119069.3A patent/CN102046200B/zh not_active Expired - Fee Related
- 2009-03-19 EP EP09727052A patent/EP2275135A4/en not_active Withdrawn
- 2009-03-19 MX MX2010010954A patent/MX2010010954A/es active IP Right Grant
- 2009-03-19 KR KR1020107024691A patent/KR101612139B1/ko not_active Expired - Fee Related
- 2009-03-19 AU AU2009233301A patent/AU2009233301B2/en not_active Ceased
- 2009-03-19 RU RU2010145177/15A patent/RU2523897C2/ru not_active IP Right Cessation
- 2009-03-19 PE PE2009000413A patent/PE20091655A1/es not_active Application Discontinuation
- 2009-03-19 NZ NZ588913A patent/NZ588913A/xx not_active IP Right Cessation
-
2010
- 2010-10-03 IL IL208451A patent/IL208451A0/en unknown
- 2010-10-27 CO CO10133385A patent/CO6300964A2/es active IP Right Grant
- 2010-11-01 CR CR11769A patent/CR11769A/es unknown
- 2010-11-03 MA MA33323A patent/MA32360B1/fr unknown
- 2010-11-04 EC EC2010010589A patent/ECSP10010589A/es unknown
- 2010-12-28 JP JP2010291590A patent/JP5506654B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN102046200A (zh) | 2011-05-04 |
| WO2009122667A1 (ja) | 2009-10-08 |
| KR101612139B1 (ko) | 2016-04-12 |
| HK1151734A1 (en) | 2012-02-10 |
| AR071003A1 (es) | 2010-05-19 |
| CN102046200B (zh) | 2015-03-25 |
| TW200950804A (en) | 2009-12-16 |
| JP5306327B2 (ja) | 2013-10-02 |
| CA2720359A1 (en) | 2009-10-08 |
| SG189754A1 (en) | 2013-05-31 |
| CL2009000647A1 (es) | 2010-06-04 |
| ECSP10010589A (es) | 2010-12-30 |
| MX2010010954A (es) | 2011-03-24 |
| US20110104157A1 (en) | 2011-05-05 |
| MA32360B1 (fr) | 2011-06-01 |
| JP2011068682A (ja) | 2011-04-07 |
| JP5506654B2 (ja) | 2014-05-28 |
| AU2009233301B2 (en) | 2014-01-23 |
| JPWO2009122667A1 (ja) | 2011-07-28 |
| AU2009233301A1 (en) | 2009-10-08 |
| KR20100132060A (ko) | 2010-12-16 |
| RU2523897C2 (ru) | 2014-07-27 |
| BRPI0911147A2 (pt) | 2019-09-24 |
| EP2275135A1 (en) | 2011-01-19 |
| RU2010145177A (ru) | 2012-05-20 |
| CR11769A (es) | 2011-03-30 |
| IL208451A0 (en) | 2010-12-30 |
| CO6300964A2 (es) | 2011-07-21 |
| UA103614C2 (uk) | 2013-11-11 |
| EP2275135A4 (en) | 2013-03-06 |
| TWI468175B (zh) | 2015-01-11 |
| NZ588913A (en) | 2012-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20091655A1 (es) | Farmaco para el cancer de higado | |
| CL2020001579A1 (es) | Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un agente tamponante, y citrato; uso de dicha formulación para tratar enfermedad inflamatoria del intestino. (divisional solicitud 201303145) | |
| PE20120899A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b | |
| AR117913A2 (es) | Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos | |
| AR075981A1 (es) | Tratamiento con un anticuerpo igg1 humanizado anti- egfr e irinotecan. composicion farmaceutica. kit. uso | |
| PE20142243A1 (es) | Anticuerpos que se unen a ox40 y sus usos | |
| PE20140247A1 (es) | Anticuerpos anti-cd38 | |
| PE20240813A1 (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodo para su uso | |
| PE20170912A1 (es) | Conjugados de anticuerpo-farmaco | |
| PE20131209A1 (es) | Anticuerpos anti-fap | |
| PE20141693A1 (es) | Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1e inhibidores de mek | |
| ECSP19025350A (es) | Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi) | |
| PE20140825A1 (es) | Anticuerpos contra il-6 y sus usos | |
| NI200900022A (es) | Anticuerpo especifico de prlr y usos del mismo | |
| PE20141560A1 (es) | Anticuerpo anti-epirregulina humanizado y agente terapeutico contra el cancer que comprende dicho anticuerpo como ingrediente activo | |
| CL2016002585A1 (es) | Inmunoconjugado que comprende una proteína de unión a antígeno que se une a antígeno de maduración de linfocitos b (bcma) y un agente citotóxico, composición farmacéutica y su uso (divisional solicitud 201303373) | |
| PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
| PE20240913A1 (es) | Anticuerpos anti-il-2r agonistas y metodos de uso | |
| PE20161571A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
| EA201891509A1 (ru) | Способы лечения рака | |
| MX380191B (es) | Combinaciones de modalidades para el tratamiento de la diabetes. | |
| CR10308A (es) | Anticuerpos monoclonales humanizados para el factor de crecimiento del hepatocito | |
| PE20140806A1 (es) | Anticuerpos anti-factor d humanizados y sus usos | |
| EA201491571A1 (ru) | МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ | |
| PE20131403A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |